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Abstract
Recent years have seen a growing interest in insulin-like growth factor 1 receptor (IGF1R) in medical oncology.
Interesting data have been reported also on IGF1r in gastrointestinal stromal tumors (GISTs) especially in children
and in young adult patients whose disease does not harbour mutations on KIT and PDGFRA and are poorly
responsive to conventional therapies. However, it is too early to reach conclusions on IGF1R as a novel therapeutic
target in GIST because the receptor’s biological role is still to be defined and the clinical significance in patients
needs to be studied in larger studies. We update and comment the current literature on IGF1R in GISTs and
discuss the future perspectives in this promising field.
Introduction
Recent years have seen a growing interest in insulin-like
growth factor 1 receptor (IGF1R) in medical oncology.
IGF1R is a tyrosine kinase receptor that binds both
IGF1 and IGF2 [1]. After ligand binding, the tyrosine
kinase domain is activated and stimulates the intracellu-
lar signaling pathways that control the proliferation rate
and apoptosis (Figure 1). Two key signal-transduction
networks have been identified: GPTase Ras-Raf-ERK/
MAPK and PI3K-AKT/mTOR [2]. The IGF system
plays a key role in the growth and development of nor-
mal tissue. However, aberrations of this molecular path-
way such as overexpression of IGF1R, elevated plasma
levels of IGF1, loss of IGF2 imprinting, or genetic poly-
morphisms of the gene encoding IGF1 have been found
in many cancers, affecting multiple aspects of malig-
nancy such as tumor growth and metastases [3,4]. The
biologic role of the IGF system in rhabdomyosarcomas,
neuroblastomas, osteosarcomas and soft-tissue sarcomas
has been widely demonstrated by preclinical and clinical
evidence [5-20]. The IGF1R pathway has also been
shown to exhibit cross-talk with a number of other sig-
naling pathways such as EGFR and HER2, suggesting a
possible role in mediating resistance to drugs targeting
these molecules [21,22]. Therefore IGF1R has been
investigated in cancer therapy and strategies for its inhi-
bition in sarcoma have already been reported [23-26].
Inhibition of IGF1R affects Ewing’s sarcoma cell growth
in vivo [27,28] and seems to sensitize sarcoma cells to
conventional agents by a synergistic interaction, suggest-
ing a therapeutic combination approach [29,30].
Although the family of sarcomas is the most investigated
field, aberrant IGFIR signaling has been implicated in
other solid tumors, including lung, breast and colon
cancer [31-35]. Interesting data have been reported on
IGF1R in gastrointestinal stromal tumors (GISTs)
[36-40]. Current literature on IGF1R in GISTs needs to
be updated with a discussion on future perspectives in
this field.
As is well known, GISTs are characterized by the
abnormalities of the KIT and PDGFRA receptors that
represent the key oncogenic event and most important
therapeutic target [41-45]. In a small subset of patients the
disease does not present any mutation and is defined as
wild-type (WT). The mutational status of KIT and
PDGFRA affects response to tyrosine kinase inhibitors and
confers primary or secondary resistance [44,45]. Recently,
IGF1R has emerged as a novel molecular signaling path-
way other than KIT and PDGFRA on GISTs [36-40]. Tarn
and colleagues evaluated IGF1R with SNPs array, FISH
and realtime PCR at genomic level, and with western blot-
ting (WB) and immunohistochemistry (IHC) at protein
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gene was amplified especially in WT GISTs compared
with mutant GISTs, including a pediatric case. To deter-
mine whether enhanced expression of IGF1R is associated
with gene amplification, they evaluated IGF1R gene copy
number in mutant and WT GISTs using a genomic-based
quantitative PCR assay. Seven of the 10 WT GISTs had
the IGF1R amplification (copy number range, 2.5-4 copies)
compared with only 5 out of 18 mutant GISTs (P = 0.04).
IGF1R gene amplification was also confirmed by FISH. No
mutations in IGF1R gene were found in the WT GISTs.
The protein level was abundantly expressed only in WT
GIST by WB and IHC (Cell Signaling antibody). Agaram
and colleagues evaluated IGF1R in 17 patients as gene
expression profiling (mRNA level) and found that it was
up-regulated in children and young adults (patients < 30
years old) [37]. We examined the IGF1R status in 8
patients with gastric GIST [38]. IGF1R was studied as
gene expression profiling performed with Affymetrix Gen-
eChip HG-U133 Plus 2.0 arrays and as genomic copy
number with SNP array analysis Affymetrix Genome
Wide Human SNP 6.0 arrays, and at protein level with
IHC (Santa Cruz Biotechnology Inc). The unsupervised
analysis of gene expression profiling in our patients
merged with a data set from a gastric GIST showed that
IGF1R was up-regulated in two young patients (< 30 years
old) with both WT disease and metastases at diagnosis,
and was confirmed by WB and IHC. SNPs array analysis
of the genomic copy number showed that neither of the 2
young patients had tumors with IGF1R amplification.
More recently, Janeway and colleagues studied IGF1R with
WB, SNP and FISH and found a strong expression of the
receptor in 8 out of 9 WT pediatric GISTs [39]. By SNP
analysis, none of the pediatric WT GISTs had IGF1R
amplification. To validate the SNP data, FISH was done in
two patients and in one additional pediatric WT GIST for
which there was insufficient fresh frozen specimen for
SNP analysis and no gene amplification was documented
in any of the 3 cases. Lastly, Braconi and colleagues evalu-
ated IHC expression of IGF1R (Santa Cruz antibody) and
its ligands IGF1 and IGF2 in 94 patients [40]. They found
that the IGF1R was strongly expressed in most cases both
WT and mutant, but the ligands showed different levels of
expression.
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Figure 1 IGF1R pathway.
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Despite the above studies, it is too early to reach con-
clusions on IGF1R as a novel therapeutic target in
GIST. Firstly, the data from these studies are related to
different levels of biological information, and secondly
they were obtained using different assays, different anti-
bodies and different scores. In addition, although we
cannot generalize, longstanding experience of EGFR in
colorectal cancer as a target and molecular predictor of
EGFR inhibitors should be considered before talking
about novel targets in medical oncology [46,47]. More-
over, to date few data have been reported on IGF1R in
GISTs and the receptor’st r u er o l ei nt h ep a t h o g e n e s i s
of the disease remains to be defined. As a consequence,
the clinical implications such as the correlation with
mutational receptors status, clinical outcome, prognosis,
therapeutic responsiveness or the exact GIST population
with IGF1R deregulation require further investigation.
First of all, the mechanism by which IGF1R is
strongly expressed in WT GISTs has not been identi-
fied. Low level amplification in 6 WT GISTs was
reported only by Tarn and colleagues [36], whereas the
other reports on IGF1R [38,39] and SNP-array data
[ 4 8 , 4 9 ]t h a tc o l l e c t i v e l ya n a l y z e d2 6p e d i a t r i co ry o u n g
adult WT GIST cases showed no gain at chromosome
15. Hence it is conceivable that IGF1R amplification
represents a rare event in WT GISTs, and that IGF1R
overexpression is reasonably sustained by other
mechanisms. The lack of genomic amplification is not
surprising, since IGF1R is not generally found ampli-
fied in human tumors [1,24]. Many mechanisms con-
tribute to IGF1R overexpression in sarcomas [24] such
as receptor upregulation or overexpression of ligands
driven by multiple mechanisms like fusion genes
(PAX3-FKHR; EWS-WT1; EWS-FLI1), loss of imprint-
ing (LOI) of IGF2, or loss of tumor suppressor genes
(WT1, PTEN, p53). IGF2 LOI deserves further investi-
gation in WT GISTs because it is an important
mechanism in many pediatric solid tumors, and
because ligand expression is found in WT GISTs [40].
The most exciting future perspectives are first to study
the biological role of IGF1R in GISTs in in vitro and
in vivo models, and second to investigate the receptor’s
clinical significance further using ex-vivo analyses (IHC,
gene expression, SNP, etc) in larger series of patients.
About the biological role, notwithstanding the very high
expression of IGF1R in GIST carrying a wild type KIT and
PDGFRA status, suggesting a possible role as a therapeutic
target, almost no experimental data are available on the
functional role and oncogenic relevance of this receptor in
GIST tumors. The only data were reported by Tarn and
colleagues who treated GIST-T1 and GIST 882 cell lines
with the IGF1R inhibitor NVP-AEW541, measuring an
IC50 of 3.7 - 3.9 μM [36]. Albeit encouraging, this result is
not predictive of any activity in GIST WT tumors, since
these cell lines poorly express IGF1R, harbor KIT muta-
tions and are dependent on aberrant KIT signaling for
proliferation and survival. In addition, the IC50 concentra-
tion is suggestive of the inhibition of tyrosine kinase tar-
gets other than IGF1R [50]. IGF1R signaling was blocked
in many other types of sarcomas to explore its role in cell
proliferation and survival in vitro, and tumor growth, inva-
sion and metastasis in vivo in animal models [25]. Unfor-
tunately preclinical studies assessing the relevance of
IGF1R in GISTs are hampered by the lack of a suitable
in vitro model of WT GIST. To overcome this problem
KIT-mutant GIST cell lines could be infected with IGF1R
vectors inducing IGF1R expression and analyzing its effect
on cell growth, proliferation, apoptosis and response to
agonists (IGF1 and IGF2) and IGF1R-inhibitors or antibo-
dies [51]. IGF1R induction could also be coupled with KIT
downregulation to explore the relationship between the
two oncogenic signaling pathways. IGF1R-transfected
GIST cell lines could also be used in vivo in suitable xeno-
graft animal models to test the efficacy of different IGF1R-
inhibitors and the effect of the combination with standard
front line therapies [52]. These analyses are particularly
necessary to confirm the putative oncogenic role of IGF1R
in WT GISTs. Indeed the possibility that IGF1R is not a
tumor-specific target, but just a stage-specific differentia-
tion marker of interstitial cell of Cajal (ICC) precursors
cannot be ruled out, since a recent work by Lorincz and
colleagues showed that ICC precursors are a rare IGF1R-
positive, Kit
(low), CD44
(+), CD34
(+), Insr
(+) cell population,
retained in postnatal life, that is dependent on IGF signal-
ing for survival and differentiation [53]. The absence of
IGF1R activating mutations or genomic amplifications in
WT GIST does not offer even indirect support of a domi-
nant oncogenic role [37-39]. Besides functional in vitro
and in vivo studies, in-depth analysis of WT GISTs geno-
mic and transcriptomic profile by microarray or next gen-
eration sequencing techniques will help to clarify IGF1R’s
role as a marker or therapeutic target, and the mechanism
of its over-expression in this rare subtype of GIST that is
poorly responsive to conventional therapies [37,48,49].
If preclinical functional studies demonstrate the
pathogenetic role of IGF1R in WT GISTs, the IGF axis
blockade may be beneficial in the treatment of GIST.
However, in-depth analysis of the IGF axis in GISTs is
mandatory, since ligand signaling could also be driven
by other receptors like insulin receptor isoform A (IR-
A), that is especially overexpressed in cancer [54], and
whose expression and function have not been investi-
gated in GISTs. Commonly, membrane receptor block-
ade can be achieved with monoclonal antibodies that
block the extracellular domain, or with tyrosine kinase
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theory, if they work both should block receptor activa-
tion, and thereby block the intracellular pathways. Of
course, direct inhibition of the molecules of these path-
ways, such as MAPK or PI3K or mTOR, is a potential
therapeutic option especially because no amplification or
kinase mutation have been identified for IGF1R. More-
over, this strategy may have an enhanced antitumor effect
s i n c eM A P K ,P I 3 Ko rm T O Rm a ya l s ob ea c t i v a t e db y
KIT and PDGFRA receptors and may overcome KIT and
PDGFRA-dependent imatinib resistance [55].
Glycemic derangements related to insulin-like growth
factors such as the pro-IGF-IIE and insulin-like growth
factor-binding proteins have been described in GISTs,
and they may become more important in patient man-
agement because of a potential cross-reactivity between
IGF1R and the insulin receptor [56-59]. Even though
metabolic derangements are uncommon and no data are
available on what might happen to glucose metabolism
after administration of IGF1R-targeted drugs, great atten-
tion should be paid to these clinical aspects and caution
exerted during therapeutic IGF1R inhibition in GIST.
Conclusions
In conclusion, a novel signaling pathway other than KIT
and PDGFRA is emerging in GISTs, and more preclini-
cal studies are needed to disclose its biological role. Lar-
ger population studies are warranted to identify patients
who may benefit from IGF1R inhibitors such as children
or also young adult WT patients. Moreover, these ana-
lyses should be centralized as was done for KIT and
PDGFRA mutational status especially because GIST is a
rare disease.
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